Mostrar el registro sencillo del ítem

dc.contributor.author
Podhorzer, Ariel  
dc.contributor.author
Dirchwolf, Melisa  
dc.contributor.author
Machicote, Andrés Pablo  
dc.contributor.author
Belen, Santiago  
dc.contributor.author
Montal, Silvina  
dc.contributor.author
Paz, Silvia  
dc.contributor.author
Fainboim, Hugo  
dc.contributor.author
Podestá, Luis G.  
dc.contributor.author
Fainboim, Leonardo  
dc.date.available
2020-01-27T23:01:01Z  
dc.date.issued
2018-01  
dc.identifier.citation
Podhorzer, Ariel; Dirchwolf, Melisa; Machicote, Andrés Pablo; Belen, Santiago; Montal, Silvina; et al.; The clinical features of patients with chronic hepatitis C virus infections are associated with killer cell immunoglobulin-like receptor genes and their expression on the surface of natural killer cells; Frontiers Media S.A.; Frontiers in Immunology; 8; 1-2018; 1-16  
dc.identifier.issn
1664-3224  
dc.identifier.uri
http://hdl.handle.net/11336/95946  
dc.description.abstract
Killer cell immunoglobulin-like receptor (KIR) genes are known to play a role in the acute phase of hepatitis C virus (HCV) infection. The present study investigated their roles in chronic HCV (CHCV) infection by analyzing the phenotypes and function of natural killer (NK) and T cells that express KIRs. T cells from CHCV patients showed a more differentiated phenotype, and NK cells exhibited an activated profile. These observations are consistent with the increased expression of the degranulation marker CD107a observed after PMA stimulation. We explored the correlations between the expression of KIR genes and lectin type-C receptors with clinical factors that predict progression to fibrosis and cirrhosis. The expression levels of KIR2DS3 and the functional alleles of KIR2DS4-FL were increased in patients with intermediate and high viral loads. Homozygous KIR2DS4 was also associated with the presence of cirrhosis. In the group of individuals with a shorter infection time who developed cirrhosis, we detected decreased expression of KIR3DL1 in CD56dim NK cells in the presence of its ligand. Similarly, in the group of patients with late CHCV infections complicated with cirrhosis, we detected lower expression of the strong inhibitory receptor NKG2A in CD56bright NK cells. We also detected an increase in NKG2C expression in CD56dim NK cells in CHCV patients who displayed high necroinflammatory activity. Decreased KIR3DL2 expression in CD56dim and CD56bright NK cells was associated with a high body mass index, and KIR3DL2 expression may be one factor associated with the more rapid progression of CHCV to fibrosis in patients.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Frontiers Media S.A.  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
CHRONIC HCV  
dc.subject
KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR  
dc.subject
LIVER  
dc.subject
NATURAL KILLER CELLS  
dc.subject
T CELLS  
dc.subject.classification
Biología Celular, Microbiología  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
The clinical features of patients with chronic hepatitis C virus infections are associated with killer cell immunoglobulin-like receptor genes and their expression on the surface of natural killer cells  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2019-10-16T20:36:33Z  
dc.journal.volume
8  
dc.journal.pagination
1-16  
dc.journal.pais
Suiza  
dc.journal.ciudad
Lausana  
dc.description.fil
Fil: Podhorzer, Ariel. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina  
dc.description.fil
Fil: Dirchwolf, Melisa. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina  
dc.description.fil
Fil: Machicote, Andrés Pablo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina  
dc.description.fil
Fil: Belen, Santiago. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina  
dc.description.fil
Fil: Montal, Silvina. Hospital Universitario Austral; Argentina  
dc.description.fil
Fil: Paz, Silvia. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina  
dc.description.fil
Fil: Fainboim, Hugo. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina  
dc.description.fil
Fil: Podestá, Luis G.. Hospital Universitario Austral; Argentina  
dc.description.fil
Fil: Fainboim, Leonardo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina  
dc.journal.title
Frontiers in Immunology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fimmu.2017.01912  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2017.01912/full